{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:4574"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:4574","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Project 1: Novel bromodomain and extra-terminal (BET) protein inhibitor JQ1 sensitises dexamethasone-resistant ALL cells to dexamethasone-induced cell killing and Does microRNA deregulation contribute to PTTGl-Binding Factor (PBF) overexpression in thyroid carcinoma? Project 2: Does microRNA deregulation contribute to PTTG1-Binding Factor (PBF) overexpression in thyroid carcinoma?","abstract":"Background: B-cell precursor acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Proto-oncogene MYC functions as a DNA binding transcriptional activator. BET family proteins facilitate MYC transcription, and have recently emerged as a potential therapeutic target in heamopoitic malignancies. JQl is a cell-permeable small molecule that binds competitively to the acetyl-lysine recognition motifs with high specificity for the bromodomains of BET family members, preventing their ability to transcribe MYC. JQI inhibitor bas previously demonstrated drastic anti-tumour activity in Vitro and in pre­ clinical models of c-Myc dependent malignancies. Aim: To investigate the sensitivity of ALL cells to JQI-mediated BET inhibition, and whether JQ1 is capable of sensitising cytotoxic agent Dexamethasone resistant ALL cells to Dexamethasone induced cell killing both in vitro and in vivo. Methods: Cytotoxicity assays were used to investigate JQl-mediated Dexamethasone sensitisation in ALL cells in vitro. A Xenograft model was used to investigate this in NOG mice in vivo.Results: JQl-dexamethasone co-treatment resulted insignificantly increased cell killing in vitro and complete tumour suppression in vivo. Discussion: JQl is capable of sensitising Dexamethasone resistant ALL cells to Dexamethasone induced cell killing both in vitro and in vivo.","abstract_html":"Background: B-cell precursor acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Proto-oncogene MYC functions as a DNA binding transcriptional activator. BET family proteins facilitate MYC transcription, and have recently emerged as a potential therapeutic target in heamopoitic malignancies. JQl is a cell-permeable small molecule that binds competitively to the acetyl-lysine recognition motifs with high specificity for the bromodomains of BET family members, preventing their ability to transcribe MYC. JQI inhibitor bas previously demonstrated drastic anti-tumour activity in Vitro and in pre­ clinical models of c-Myc dependent malignancies. Aim: To investigate the sensitivity of ALL cells to JQI-mediated BET inhibition, and whether JQ1 is capable of sensitising cytotoxic agent Dexamethasone resistant ALL cells to Dexamethasone induced cell killing both in vitro and in vivo. Methods: Cytotoxicity assays were used to investigate JQl-mediated Dexamethasone sensitisation in ALL cells in vitro. A Xenograft model was used to investigate this in NOG mice in vivo.Results: JQl-dexamethasone co-treatment resulted insignificantly increased cell killing in vitro and complete tumour suppression in vivo. Discussion: JQl is capable of sensitising Dexamethasone resistant ALL cells to Dexamethasone induced cell killing both in vitro and in vivo.","abstract_has_math":false,"creators":["Longman, Joanna"],"institution":"University of Birmingham","degree_name":"m_rs","degree_level":"m_rs","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-12","date_published":"2013-12","updated_at":"2026-11-19T09:27:45Z","subjects":["R Medicine (General)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/4574/1/Longman13MRes.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A4574","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Longman, Joanna"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013-12"]},{"key":"dc:date.issued","label":"Date","values":["2013-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Clinical and Experiment Medicine, Department of Medicine and Medical Education"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/4574/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_rs"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_rs"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["R Medicine (General)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/4574/1/Longman13MRes.pdf","http://etheses.bham.ac.uk//id/eprint/4574/5/Decl_IS_Longman13MRes.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background: B-cell precursor acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Proto-oncogene MYC functions as a DNA binding transcriptional activator. BET family proteins facilitate MYC transcription, and have recently emerged as a potential therapeutic target in heamopoitic malignancies. JQl is a cell-permeable small molecule that binds competitively to the acetyl-lysine recognition motifs with high specificity for the bromodomains of BET family members, preventing their ability to transcribe MYC. JQI inhibitor bas previously demonstrated drastic anti-tumour activity in Vitro and in pre­ clinical models of c-Myc dependent malignancies. Aim: To investigate the sensitivity of ALL cells to JQI-mediated BET inhibition, and whether JQ1 is capable of sensitising cytotoxic agent Dexamethasone resistant ALL cells to Dexamethasone induced cell killing both in vitro and in vivo. Methods: Cytotoxicity assays were used to investigate JQl-mediated Dexamethasone sensitisation in ALL cells in vitro. A Xenograft model was used to investigate this in NOG mice in vivo.Results: JQl-dexamethasone co-treatment resulted insignificantly increased cell killing in vitro and complete tumour suppression in vivo. Discussion: JQl is capable of sensitising Dexamethasone resistant ALL cells to Dexamethasone induced cell killing both in vitro and in vivo."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","validuser"]},{"key":"dc:title","label":"Title","values":["Project 1: Novel bromodomain and extra-terminal (BET) protein inhibitor JQ1 sensitises dexamethasone-resistant ALL cells to dexamethasone-induced cell killing and Does microRNA deregulation contribute to PTTGl-Binding Factor (PBF) overexpression in thyroid carcinoma? Project 2: Does microRNA deregulation contribute to PTTG1-Binding Factor (PBF) overexpression in thyroid carcinoma?"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Longman, Joanna"],"dc:date":["2013-12"],"dc:date.issued":["2013-12"],"dc:description.abstract":["Background: B-cell precursor acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Proto-oncogene MYC functions as a DNA binding transcriptional activator. BET family proteins facilitate MYC transcription, and have recently emerged as a potential therapeutic target in heamopoitic malignancies. JQl is a cell-permeable small molecule that binds competitively to the acetyl-lysine recognition motifs with high specificity for the bromodomains of BET family members, preventing their ability to transcribe MYC. JQI inhibitor bas previously demonstrated drastic anti-tumour activity in Vitro and in pre­ clinical models of c-Myc dependent malignancies. Aim: To investigate the sensitivity of ALL cells to JQI-mediated BET inhibition, and whether JQ1 is capable of sensitising cytotoxic agent Dexamethasone resistant ALL cells to Dexamethasone induced cell killing both in vitro and in vivo. Methods: Cytotoxicity assays were used to investigate JQl-mediated Dexamethasone sensitisation in ALL cells in vitro. A Xenograft model was used to investigate this in NOG mice in vivo.Results: JQl-dexamethasone co-treatment resulted insignificantly increased cell killing in vitro and complete tumour suppression in vivo. Discussion: JQl is capable of sensitising Dexamethasone resistant ALL cells to Dexamethasone induced cell killing both in vitro and in vivo."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/4574/1/Longman13MRes.pdf","http://etheses.bham.ac.uk//id/eprint/4574/5/Decl_IS_Longman13MRes.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Clinical and Experiment Medicine, Department of Medicine and Medical Education"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/4574/"],"dc:subject":["R Medicine (General)"],"dcterms:accessrights":["public","validuser"],"dc:title":["Project 1: Novel bromodomain and extra-terminal (BET) protein inhibitor JQ1 sensitises dexamethasone-resistant ALL cells to dexamethasone-induced cell killing and Does microRNA deregulation contribute to PTTGl-Binding Factor (PBF) overexpression in thyroid carcinoma? Project 2: Does microRNA deregulation contribute to PTTG1-Binding Factor (PBF) overexpression in thyroid carcinoma?"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_rs"],"dc:type.qualificationname":["m_rs"]},"updated_at":"2026-11-19T09:27:45Z"}